RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)
In a report released on January 7, Gregory Renza from RBC Capital maintained a Buy rating on Cormedix (CRMD – Research Report), with a price ...
Financial Services Roundup: Market Talk
Find insight on BBVA, Australia’s banks and more in the latest Market Talks covering Financial Services.
EconoTimes1d
RBC Upgrades Utilities Sector While Downgrading Energy
RBC Capital Markets has upgraded the Utilities sector to Overweight, naming it the top defensive sector, while downgrading ...
RBC Capital Sticks to Their Hold Rating for Moderna (MRNA)
In a report released on January 7, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
Invitation Homes price target lowered to $33 from $34 at RBC Capital
RBC Capital lowered the firm’s price target on Invitation Homes (INVH) to $33 from $34 and keeps a Sector Perform rating on ...
E&E1d
Exxon drops after warning of oil, refining hit to 4Q profit
Exxon Mobil’s shares fell after the company warned its fourth-quarter earnings will take a hit from lower crude prices and narrowing refining margins during the final three months of 2024.
RBC quantitative analyst makes 10 changes to his top 40 Canadian stock picks
Scotiabank analyst Mario Saric thinks the worst may be over for domestic office REITs, ...
Centerspace price target lowered to $72 from $76 at RBC Capital
RBC Capital analyst Brad Heffern lowered the firm’s price target on Centerspace (CSR) to $72 from $76 and keeps an Outperform ...
RBC Capital Remains a Buy on Nasdaq (NDAQ)
RBC Capital analyst Ashish Sabadra maintained a Buy rating on Nasdaq (NDAQ – Research Report) yesterday and set a price target of $95.00. The ...